ZDHHC2

Across TCGA pan-cancer cohorts, ZDHHC2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZDHHC2 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ZDHHC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZDHHC2 expression acts as an unfavorable survival marker.

SCLC, PRAD, and UCEC are the cancer types where ZDHHC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.192	0.699	.002	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.193	0.515	.007	6	view →
LIHC	DFS	Median	All	0.096	0.526	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZDHHC2–SCLC (OS)

Open the SCLC breakdown →